TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...
The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.
Bain Capital is making its latest biotech bid in Japan, where it plans to acquire Mitsubishi Tanabe Pharma Corp. The Boston-based private investment firm is buying Tanabe Pharma from Mitsubishi ...
TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...
You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...
Dwelling on what the future may hold can create an unbearable fear.” Through Mitsubishi Tanabe Pharma America’s Share Your Story program, people living with ALS and their caregivers can share ...
Mitsubishi Tanabe Pharma and bluebird bio were both bought by investors during the month, while private equity firms ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback